CompletedPhase 4

Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis

Thailand80 participantsStarted 2010-03

Plain-language summary

The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Having a psychotic episode with current use of methamphetamine * Positive urine toxicology test for methamphetamine on the first day of hospitalization Exclusion Criteria: * Using other illegal substances * Having a history of primary psychotic disorders or using antipsychotic agents * Having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy, stroke

What they're measuring

Positive and Negative Syndrome Scale

Timeframe: Every day in Week 1.

Positive and Negative Syndrome Scale

Timeframe: Every two days in Week 2 and 3.

Trial details

NCT IDNCT01939093

SponsorChulalongkorn University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-09

View on ClinicalTrials.gov More Methamphetamine-induced Psychosis trials